<DOC>
<DOCNO>EP-0635491</DOCNO> 
<TEXT>
<INVENTION-TITLE>
(Thia) cycloalkyl(b)indoles, process of their preparation and compositions containing it
</INVENTION-TITLE>
<CLASSIFICATIONS>A61P3700	A61K31403	A61P4300	C07D49504	A61P900	A61P2900	A61P4300	A61K3140	A61P900	A61K3140	C07D20900	C07D49500	A61K31403	C07D20994	A61P2900	A61P3708	</CLASSIFICATIONS>
<CLASSIFICATIONS-THIRD>A61P	A61K	A61P	C07D	A61P	A61P	A61P	A61K	A61P	A61K	C07D	C07D	A61K	C07D	A61P	A61P	</CLASSIFICATIONS-THIRD>
<CLASSIFICATIONS-FOURTH>A61P37	A61K31	A61P43	C07D495	A61P9	A61P29	A61P43	A61K31	A61P9	A61K31	C07D209	C07D495	A61K31	C07D209	A61P29	A61P37	</CLASSIFICATIONS-FOURTH>
<ABSTRACT>
The invention relates to the compounds of formula (I): 
<
IMAGE
>
  in which R1, R2, R3 and A are as defined in the description. Medicaments.
</ABSTRACT>
<APPLICANTS>
</APPLICANTS>
<INVENTORS>
</INVENTORS>
<CLAIMS>
Compounds of formula (I): 

 
wherein: 


A represents an alkylene chain -(CH
2
)
m
- in which 
m
 
is 5 or 6, or a group of the formula (Î±) 


 
in which 
p
 is from 1 to 4, 
R
1
 represents a radical selected from: 

hydroxy 
thiol 
-O-R
4
 wherein R
4
 is selected from alkyl and acyl; 
and -S-R
5
 wherein R
5
 is selected from alkyl, 
phenyl and benzyl; 
R
2
 represents a radical selected from hydrogen, 
halogen, alkyl, alkoxy and trifluoromethyl; 
R
3
 represents a radical selected from alkyl, acyl, 
carboxyalkyl and alkoxycarbonylalkyl; and, when A is 

other than pentamethylene, R
3
 may also represent 
hydrogen, 
  
 

with the proviso that if 
m
 is 5, R
2
 is hydrogen and R
1
 
is methoxy, then R
3
 cannot be methyl,
 
their optical isomers, in pure form or in the form of a 

mixture, when R
1
, R
2
 or R
3
 have a chiral centre,
 
and their addition salts with a pharmaceutically 

acceptable base,
 
it being understood that the terms "alkyl", "alkoxy" and 

"acyl" represent linear or branched groups having from 1 
to 6 carbon atoms. 
Compounds according to claim 1 in which A represents 
a pentamethylene chain,
 
their optical isomers in pure form or in the form of a 

mixture, and the addition salts thereof with a pharmaceutically 
acceptable base. 
Compounds according to claim 1 in which A represents 
a pentamethylene chain and R
1
 represents hydroxy, their 
optical isomers in pure form or in the form of a mixture, 

and their addition salts thereof with a pharmaceutically 
acceptable base. 
Compound according to claim 1 that is 3-hydroxy-10-methyl-5,6,7,8,9,10-hexahydro-cyclohept[
b
]indole 

and its 
addition salts with a pharmaceutically acceptable base. 
Compound according to claim 1 that is 3-methoxy-10-methyl-5,6,7,8,9,10,11-heptahydrocyclooct[
b
]indole. 
Compound according to claim 1 that is 8-methoxythiopyrano[3,2-
b
]indole. 
Compound according to claim 1 that is 2-(8-methoxy-thiopyrano[3,2-
b
]indol-5-yl) 

ethyl acetate.  
 
Process for the preparation of the compounds of 
formula (I) according to claim 1, characterised in that 

a compound of formula (II): 

 
wherein R
2
 and A are as defined in claim 1, R
1
' is 
selected from -O-R
4
 and -S-R
5
, in which R
4
 and R
5
 are as 
defined in claim 1, and X represents a halogen atom, is 

condensed in the presence of a base, such as an alkali 
metal amide or an alkali metal amide combined with an 

alkali metal alcoholate (complex base), preferably the 
complex base NaNH
2
-t.BuONa, to yield: 

either a compound of formula (III): 

 
wherein R
2
, A and R
1
' are as defined above, 
or, after hydrolysis, a compound of formula (I
a
): 

  
 

wherein R
2
, A and R
1
' are as defined above,
 
which compound of formula (III), or compound of formula 

(I
a
) in the form of its alkali metal salt, is substituted 
on the indole nitrogen by a radical of the formula R
3
' 
in which R
3
' has the same meaning as R
3
 as defined in 
claim 1 with the exception of hydrogen, in order to 

obtain a compound of formula (I
a
'): 

 
wherein R
2
, A, R
1
' and R
3
' are as defined above,
 
which compounds of formulae (I
a
) and (I
a
') are, if 
necessary, 
either subjected to a dealkylation reaction in order 
to obtain a compound of formula (I
b
): 

 
wherein R
2
, R
3
 and A are as defined above and R
1
" 
represents a hydroxy or thiol group, 
or subjected to the action of a mixture of 
formula (IV): 


Al X'
3
, R
5
'SH
 
wherein X' represents halogen and R
5
' represents 
alkyl, phenyl or benzyl,
 
to obtain, depending on the conditions of use of the  

 
compound of formula (IV): 


a compound of formula (I
b
) as defined above, 
or a compound of formula (I
c
): 

 
wherein R
2
, R
3
, R
5
' and A are as defined above,
 
which compound of formula (Ic) may be subjected to 

hydrogenation to obtain a compound of formula (I
d
): 

 
wherein R
2
, R
3
 and A are as defined above,
 
it being understood that the terms "alkyl", "alkoxy" and 

"acyl" represent linear or branched groups having from 1 
to 6 carbon atoms,
 
the compounds of formula (I
a
), (I
a
'), (I
b
), (I
c
) and (I
d
) 
forming the totality of the compounds of formula (I) 

according to claim 1,
 
which compounds of formula (I) may, where appropriate, 

be: 
purified in accordance with one or more methods 
selected from crystallisation, chromatography on a 

silica column, extraction, filtration and passage 
over carbon or resin,  

 
separated, in pure form or in the form of a mixture, 
into their possible optical isomers, 
and converted into their salts with a pharmaceutically 
acceptable base. 
Pharmaceutical compositions comprising a compound of 
formula (I) according to claim 1, or an addition salt 

thereof with a pharmaceutically acceptable base or acid, 
in combination with one or more pharmaceutically acceptable 

excipients. 
Pharmaceutical compositions according to claim 9 for 
use in disorders in which a peroxidation phenomenon, 

especially lipid peroxidation, is involved. 
Pharmaceutical compositions according to claim 9 for 
use in the treatment or prevention of disorders due to 

or associated with such peroxidation phenomena, 
especially cerebral, renal or cardiac ischaemic 

disorders, atherosclerosis, haemolytic anaemia, damage 
due to the reperfusion process and inflammatory 

syndromes. 
Pharmaceutical compositions according to claim 9 for 
use in the treatment and prevention of chronic or acute 

articular, pulmonary, cutaneous or renal inflammation, 
and especially in the prevention and treatment of 

arthritis, rheumatoid polyarthritis, osteoarthrosis, 
psoriasis, allergic disorders, asthma, inflammatory 

disorders of the intestine, gastro-intestinal ulcers, 
ischaemia, atherosclerosis, respiratory distress and 

septic shock. 
</CLAIMS>
</TEXT>
</DOC>
